Celldex Sinks As Lead Asset Rintega Fails In Phase III
This article was originally published in Scrip
Executive Summary
Celldex Therapeutics Inc.'s stock was cut by more than half to $3.79 per share after the company revealed that it would discontinue the Phase III clinical trial known as ACT IV for the cancer vaccine Rintega (rindopepimut) based on an interim assessment of survival for glioblastoma (GBM) patients.